Cervical Incompetence in Pregnancy as Antepartum ConditionPhase 4PRILOCCNCT04394533
Hyperbaric Prilocaine Compared With Hyperbaric Bupivacaine in Cervical Cerclage?
A Phase 4 study testing Prilocaine (Hyperbaric 2%) and Bupivacaine (Hyperbaric 0.5%) in people with Cervical Incompetence in Pregnancy as Antepartum Condition, run by Guy's and St Thomas' NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
Patients that have a "cervical stitch" (cervical cerclage) require an anaesthetic. The most common choice is a spinal block. This is an injection in the back that makes the lower half of the body become temporarily numb and weak. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Cervical Incompetence in Pregnancy as Antepartum Condition
- What is being tested?
- Prilocaine (Hyperbaric 2%) and Bupivacaine (Hyperbaric 0.5%)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 129 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 27 Aug 2021to 20 Aug 2025
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Healthy (ASA score 2 or 3) pregnant women presenting for elective cervical cerclage under SAB.
- Age > 18 years
Who cannot join
- Inability to read or understand the patient information sheet (PIS)
- Age < 18 years
- Unable or unwilling to consent to participation
- non-elective procedure
- serious co-morbidities (ASA score 4 or above)
- any contraindication to SAB, e.g. local or generalised infection, active central nervous system disease, coagulation disorders or anti-coagulant medication
Show all 9Show fewer
- any history of allergic reaction to any of the medications in the protocol
- concomitant use of class III anti-arrhythmics (sulfonamides, antimalarials, sodium nitroprussate, nitroglycerin, other local anaesthetics)
- any contraindication to the use of bupivacaine or prilocaine as listed in the SmPCs.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Guy's and St Thomas' NHS Foundation Trust
London, SE1 7RT
About this study
Official title: Does Subarachnoid Administration of Hyperbaric Prilocaine Produce an Improved Recovery From Anaesthesia When Compared With Hyperbaric Bupivacaine When Used to Make Cervical Cerclage Easier in Pregnant Women at Risk of Pre-term Loss?
Patients that have a "cervical stitch" (cervical cerclage) require an anaesthetic. The most common choice is a spinal block. This is an injection in the back that makes the lower half of the body become temporarily numb and weak. The key aims when choosing which type of anaesthetic are safety for mother and baby, comfort during and after the procedure as well as patient convenience and satisfaction. There are two commonly available choices for the drug used in spinal anaesthesia, bupivacaine and prilocaine. Both have a long history of being safe and effective. One difference observed in studies of these drugs used for spinal anaesthetics in other surgeries is that prilocaine is shorter-acting and it, therefore, takes less time for the return of full strength and sensation of the lower body. This means patients are able to leave hospital sooner and are less likely to need a urinary catheter. The investigators want to see if these benefits can apply to patients having a cervical stitch too, by comparing the recovery of patients having a spinal anaesthetic with one of these two local anaesthetic medications.
Read the detailed description
Cervical incompetence is defined as the inability to sustain a pregnancy to full term. It is characterized by recurrent second-trimester pregnancy losses. Cervical cerclage is a procedure that is commonly carried out in order to prevent pre-term loss in at-risk pregnancies. The major challenge of performing this as a day case procedure is achieving adequate anaesthesia for comfortable performance of the cerclage whilst providing adequate regression of motor and sensory blocks to allow ambulation and bladder control within an appropriate timescale. Spinal anaesthesia, or subarachnoid block (SAB), is commonly employed to facilitate a wide variety of pelvic and lower limb surgeries. In the United Kingdom, the commonly administered subarachnoid agents are bupivacaine, prilocaine and, until recent decades, lidocaine. The duration of action of bupivacaine makes it less well suited to day surgery as it is often difficult to reach discharge criteria within a convenient time frame. The investigators aim to examine the recovery profiles of two equipotent doses of hyperbaric prilocaine and bupivacaine. Given the evidence, the survey of practice in other centres and the commonly used doses at this institution the following regimens will be compared:
- 40 mg of hyperbaric 2% prilocaine with 15 mcg of fentanyl (intervention) and
- 10 mg of hyperbaric 0.5% bupivacaine with 15 mcg of fentanyl (comparator).
Primary Objective:
This study aims to determine if a difference exists between the time required for regression of motor block between two commonly used and equipotent doses of subarachnoid hyperbaric prilocaine and bupivacaine.
- The hypothesis is that SAB with hyperbaric 2% prilocaine will result in a clinically significant reduction in time taken for regression of motor blockade, as determined by achieving a Bromage score* of I, when compared to an equipotent dose of hyperbaric bupivacaine when used to facilitate cervical cerclage in pregnant women in the second trimester of pregnancy.
- The null hypothesis is that no clinically significant difference exists while the alternative hypothesis is that such a difference truly exists.
Secondary Objectives:
- To compare the intraoperative characteristics of the subarachnoid block and quality of intraoperative anaesthesia in the two groups.
- To compare the recovery profiles in the two groups
- To compare the incidence of complications in the two groups
- To compare the satisfaction of the participants in each group This is a prospective, single centre, parallel group, double-blind, randomised, controlled, superiority trial. The sample size will consist of 135 patients having elective cervical cerclage, under SAB, due to cervical incompetence.
Sample Size Calculation The primary outcome measurement is the comparison of the difference in time taken for regression of lower limb motor block with hyperbaric (heavy) 2% prilocaine compared to hyperbaric (heavy) 0.5% bupivacaine. Assuming, based on pilot data, that the time to regression of motor block has a standard deviation of up to 60 mins; complete data on 128 participants (64 to each arm) would give 80% power to detect a plausible and clinically important 30-min difference between groups at the 0.05 significance level. To allow for up to 5% dropout, the study will recruit 135 women.
Random allocation to groups will be achieved using "Castor" randomisation software. The sequence will have been previously determined, prior to recruitment, using computer software, by random permuted blocks. Subsequently, the subjects who give written informed consent will be randomly assigned a unique 3-digit subject number. The subject number together uniquely identifies every subject eligible for the study. Randomisation will take place on the day of surgery by a non-operating healthcare professional who will randomise according to the "Castor" software. If code breaking is necessary, this will be done by pharmacy. As soon as 128 evaluable subjects have been included in the study, recruitment will be stopped.
Analysis After checking for normality by standard diagnostic plots, a comparison between the groups will be made using multiple regression with a dummy variable for treatment arm. A correction will be made for unequal variance using the robust standard errors. Adjustment will be made for maternal BMI and height, as these are known to be related to anaesthetic effect.
No power calculation has been carried out for the secondary outcomes, and no priority is made between them. Continuous measures, including the patient satisfaction score, will be analysed as described above for the primary outcome. Binary measures will be expressed as percentages, and compared by means of risk ratios, using binary regression with a log link, adjusted for BMI and height, as described above.
Subgroup analyses: A comparison will be made between normal weight and obese women (BMI over 30 kg.m-2); and between women above and below 165 cm in height, using an interaction test to check for a difference in treatment effect.
No interim analysis is planned.
- Being tested
- Prilocaine (Hyperbaric 2%), Bupivacaine (Hyperbaric 0.5%)
- Keywords
- cervical incompetence, cervical cerclage, bupivacaine, prilocaine, subarachnoid block
- Medical subject headings
- Uterine Cervical Incompetence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prilocaine (Hyperbaric 2%)Drug
Also called Hyperbaric prilocaine
2 ml hyperbaric prilocaine
Bupivacaine (Hyperbaric 0.5%)Drug
Also called Heavy bupivacaine 0.5%, heavy marcaine 0.5%
2 ml hyperbaric bupivacaine
| Study group | Role | What they receive |
|---|---|---|
| Prilocaine (Intervention) Group | Experimental | Subarachnoid block (SAB) with 40 mg (2 ml) of hyperbaric 20 mg/ml prilocaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml) Receives: Drug: Prilocaine (Hyperbaric 2%) |
| Bupivacaine (Control) Group | Active comparator | Subarachnoid block (SAB) with 10 mg (2 ml) of hyperbaric 5 mg/ml bupivacaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml) Receives: Drug: Bupivacaine (Hyperbaric 0.5%) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time from SAB to Bromage score of I
Difference in time taken for regression of lower limb block between the two groups
Measured: 24 hours
Secondary outcomes (8)
Time from SAB until loss of cold sensation to ethyl chloride spray at tenth thoracic dermatomal level (T10)
Difference in time (minutes) for loss of cold sensation at tenth thoracic dermatomal level (T10)
Measured: 30 minutes
Time from SAB until motor block Bromage IV
Difference in time take for complete motor block to occur
Measured: 30 minutes
Determine uppermost level of sensory block
Determine uppermost (cephalad) dermatomal level of sensory block as measured by loss of cold sensation to ethyl chloride spray at 20 minutes (mean).
Measured: 20 minutes
Degree of motor block
Mean degree of motor block as assessed on the Bromage scale at 20 minutes (from I-IV)
Measured: 20 minutes
Maximum intraoperative Numerical Rating Score (NRS) [0-10]
Mean pain score on the NRS (from 0-10) of maximal discomfort experienced during the procedure
Measured: 1 hour
Time from SAB to ambulation
Mean time in minutes from SAB to ambulation
Measured: 24 hours
Time from SAB to micturition
Mean time in minutes from SAB to micturition
Measured: 24 hours
Time from SAB to discharge
Mean time in minutes from SAB to discharge
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2020
- Study start27 Aug 2021
- Primary completion20 Aug 2025
- Study completion20 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical Incompetence in Pregnancy as Antepartum ConditionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, parallel group, double-blind, randomised, controlled, superiority trial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 129 participants (actual)
Sponsor and investigators
- Lead sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Obstetric Anaesthetists' Association United Kingdom
- Responsible party
- Sponsor
- Investigators
- Desire Onwochei, MBBS, Principal investigator, Guy's and St Thomas' NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04394533
- Sponsor's protocol ID
- 225703
- Other IDs
- 2019-001548-23, 2019
- Acronym
- PRILOCC
- Status last verified
- Jun 2026
- First submitted
- 14 May 2020
- Last updated
- 8 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does Subarachnoid Administration of Hyperbaric Prilocaine Produce an Improved Recovery From Anaesthesia When Compared With Hyperbaric Bupivacaine When Used to Make Cervical Cerclage Easier in Pregnant Women at Risk of Pre-term Loss?
- ClinicalTrials.gov ID
- NCT04394533
- Acronym / sponsor ID
- PRILOCC / 225703
- Keywords
- cervical incompetence, cervical cerclage, bupivacaine, prilocaine, subarachnoid block
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 129 participants (actual)
- Lead sponsor
- Guy's and St Thomas' NHS Foundation TrustUniversity, hospital or other
- Collaborators
- Obstetric Anaesthetists' Association United Kingdom
- Study start
- 27 Aug 2021 (actual)
- Primary completion
- 20 Aug 2025 (actual)
- Study completion
- 20 Aug 2025 (actual)
- First posted
- 19 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients that have a "cervical stitch" (cervical cerclage) require an anaesthetic. The most common choice is a spinal block. This is an injection in the back that makes the lower half of the body become temporarily numb and weak. The key aims when choosing which type of anaesthetic are safety for mother and baby, comfort during and after the procedure as well as patient convenience and satisfaction. There are two commonly available choices for the drug used in spinal anaesthesia, bupivacaine and prilocaine. Both have a long history of being safe and effective. One difference observed in studies of these drugs used for spinal anaesthetics in other surgeries is that prilocaine is shorter-acting and it, therefore, takes less time for the return of full strength and sensation of the lower body. This means patients are able to leave hospital sooner and are less likely to need a urinary catheter. The investigators want to see if these benefits can apply to patients having a cervical stitch too, by comparing the recovery of patients having a spinal anaesthetic with one of these two local anaesthetic medications.
Detailed description
Cervical incompetence is defined as the inability to sustain a pregnancy to full term. It is characterized by recurrent second-trimester pregnancy losses. Cervical cerclage is a procedure that is commonly carried out in order to prevent pre-term loss in at-risk pregnancies. The major challenge of performing this as a day case procedure is achieving adequate anaesthesia for comfortable performance of the cerclage whilst providing adequate regression of motor and sensory blocks to allow ambulation and bladder control within an appropriate timescale. Spinal anaesthesia, or subarachnoid block (SAB), is commonly employed to facilitate a wide variety of pelvic and lower limb surgeries. In the United Kingdom, the commonly administered subarachnoid agents are bupivacaine, prilocaine and, until recent decades, lidocaine. The duration of action of bupivacaine makes it less well suited to day surgery as it is often difficult to reach discharge criteria within a convenient time frame. The investigators aim to examine the recovery profiles of two equipotent doses of hyperbaric prilocaine and bupivacaine. Given the evidence, the survey of practice in other centres and the commonly used doses at this institution the following regimens will be compared:
- 40 mg of hyperbaric 2% prilocaine with 15 mcg of fentanyl (intervention) and
- 10 mg of hyperbaric 0.5% bupivacaine with 15 mcg of fentanyl (comparator).
Primary Objective:
This study aims to determine if a difference exists between the time required for regression of motor block between two commonly used and equipotent doses of subarachnoid hyperbaric prilocaine and bupivacaine.
- The hypothesis is that SAB with hyperbaric 2% prilocaine will result in a clinically significant reduction in time taken for regression of motor blockade, as determined by achieving a Bromage score* of I, when compared to an equipotent dose of hyperbaric bupivacaine when used to facilitate cervical cerclage in pregnant women in the second trimester of pregnancy.
- The null hypothesis is that no clinically significant difference exists while the alternative hypothesis is that such a difference truly exists.
Secondary Objectives:
- To compare the intraoperative characteristics of the subarachnoid block and quality of intraoperative anaesthesia in the two groups.
- To compare the recovery profiles in the two groups
- To compare the incidence of complications in the two groups
- To compare the satisfaction of the participants in each group This is a prospective, single centre, parallel group, double-blind, randomised, controlled, superiority trial. The sample size will consist of 135 patients having elective cervical cerclage, under SAB, due to cervical incompetence.
Sample Size Calculation The primary outcome measurement is the comparison of the difference in time taken for regression of lower limb motor block with hyperbaric (heavy) 2% prilocaine compared to hyperbaric (heavy) 0.5% bupivacaine. Assuming, based on pilot data, that the time to regression of motor block has a standard deviation of up to 60 mins; complete data on 128 participants (64 to each arm) would give 80% power to detect a plausible and clinically important 30-min difference between groups at the 0.05 significance level. To allow for up to 5% dropout, the study will recruit 135 women.
Random allocation to groups will be achieved using "Castor" randomisation software. The sequence will have been previously determined, prior to recruitment, using computer software, by random permuted blocks. Subsequently, the subjects who give written informed consent will be randomly assigned a unique 3-digit subject number. The subject number together uniquely identifies every subject eligible for the study. Randomisation will take place on the day of surgery by a non-operating healthcare professional who will randomise according to the "Castor" software. If code breaking is necessary, this will be done by pharmacy. As soon as 128 evaluable subjects have been included in the study, recruitment will be stopped.
Analysis After checking for normality by standard diagnostic plots, a comparison between the groups will be made using multiple regression with a dummy variable for treatment arm. A correction will be made for unequal variance using the robust standard errors. Adjustment will be made for maternal BMI and height, as these are known to be related to anaesthetic effect.
No power calculation has been carried out for the secondary outcomes, and no priority is made between them. Continuous measures, including the patient satisfaction score, will be analysed as described above for the primary outcome. Binary measures will be expressed as percentages, and compared by means of risk ratios, using binary regression with a log link, adjusted for BMI and height, as described above.
Subgroup analyses: A comparison will be made between normal weight and obese women (BMI over 30 kg.m-2); and between women above and below 165 cm in height, using an interaction test to check for a difference in treatment effect.
No interim analysis is planned.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Prospective, parallel group, double-blind, randomised, controlled, superiority trial
| Arm | Type | Receives |
|---|---|---|
| Prilocaine (Intervention) Group | Experimental | Drug: Prilocaine (Hyperbaric 2%)Subarachnoid block (SAB) with 40 mg (2 ml) of hyperbaric 20 mg/ml prilocaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml) |
| Bupivacaine (Control) Group | Active comparator | Drug: Bupivacaine (Hyperbaric 0.5%)Subarachnoid block (SAB) with 10 mg (2 ml) of hyperbaric 5 mg/ml bupivacaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml) |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Healthy (ASA score 2 or 3) pregnant women presenting for elective cervical cerclage under SAB.
- Age > 18 years
Key exclusion criteria (9 listed)
- Inability to read or understand the patient information sheet (PIS)
- Age < 18 years
- Unable or unwilling to consent to participation
- non-elective procedure
- serious co-morbidities (ASA score 4 or above)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prilocaine (Hyperbaric 2%)Also: Hyperbaric prilocaine2 ml hyperbaric prilocaine | Drug | Prilocaine (Intervention) Group |
| Bupivacaine (Hyperbaric 0.5%)Also: Heavy bupivacaine 0.5%, heavy marcaine 0.5%2 ml hyperbaric bupivacaine | Drug | Bupivacaine (Control) Group |
Primary outcome
Time from SAB to Bromage score of I
Time frame: 24 hours
Difference in time taken for regression of lower limb block between the two groups
8 secondary outcomes
Time from SAB until loss of cold sensation to ethyl chloride spray at tenth thoracic dermatomal level (T10)
Time frame: 30 minutes
Time from SAB until motor block Bromage IV
Time frame: 30 minutes
Determine uppermost level of sensory block
Time frame: 20 minutes
Degree of motor block
Time frame: 20 minutes
Maximum intraoperative Numerical Rating Score (NRS) [0-10]
Time frame: 1 hour
Time from SAB to ambulation
Time frame: 24 hours
Time from SAB to micturition
Time frame: 24 hours
Time from SAB to discharge
Time frame: 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Desire Onwochei, MBBS principal investigator
Guy's and St Thomas' NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Prilocaine (Hyperbaric 2%) and Bupivacaine (Hyperbaric 0.5%) in people with Cervical Incompetence in Pregnancy as Antepartum Condition, run by Guy's and St Thomas' NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time from SAB to Bromage score of I (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2026.